Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

177.99 -4.65 (-2.55%)
Streaming Delayed Price Updated: 3:12 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric... 
Via MarketMinute
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 ↗
Axsome Therapeutics shareholders got a New Year's gift from the FDA. 
Via The Motley Fool
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
Where Axsome Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 4, 2025 ↗
 
Via Benzinga
News headline image
Axsome Advances Toward FDA Filing For Drug To Treat Narcolepsy ↗
AXS-12 is being developed to treat cataplexy in narcolepsy by targeting norepinephrine and dopamine activity in the brain. 
Via Stocktwits
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
A Look at Axsome Therapeutics's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗
These drugmakers are poised to profit from their innovative engines. 
Via The Motley Fool
News headline image
Axsome (AXSM) Q3 2025 Earnings Call Transcript ↗
Axsome (AXSM) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
2 Monster Stocks in the Making ↗
There might still be time to get in on the ground floor. 
Via The Motley Fool
News headline image
Axsome Therapeutics Inc (NASDAQ:AXSM) Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗
Axsome Therapeutics Q3 2025 results: Revenue beat expectations with strong product sales, but the company reported a wider-than-expected loss. 
Via Chartmill
News headline image
Uncovering Potential: Axsome Therapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years ↗
Both should have significant catalysts by the end of the decade. 
Via The Motley Fool
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years ↗
Both companies have made significant progress in recent years. 
Via The Motley Fool
News headline image
A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 8 Analysts ↗
 
Via Benzinga
News headline image
Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years ↗
FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025. 
Via Benzinga
News headline image
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings ↗
 
Via Benzinga
News headline image
Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q2 2025 Revenue Beat and Narrower EPS Loss, Shares Surge 6% in Pre-Market Trading ↗
Axsome Therapeutics beats Q2 2025 revenue estimates with $150M, driven by Auvelity's 84% YoY growth. Shares rise 6% pre-market on improved EPS. 
Via Chartmill
News headline image
Axsome (AXSM) Q2 Revenue Soars 72% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now ↗
Via The Motley Fool
News headline image
Where Axsome Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required ↗
The FDA rejected Axsome's AXS-14 fibromyalgia, prompting a new trial and pushing the expected drug launch to 2028. 
Via Benzinga
News headline image
Demystifying Axsome Therapeutics: Insights From 11 Analyst Reviews ↗
 
Via Benzinga
News headline image
Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability ↗
The regulator said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review. 
Via Stocktwits
Topics Stocks
News headline image
2 Soaring Stocks Wth More Upside Potential ↗
Via The Motley Fool
News headline image
Why Is Teva Stock Trading Higher On Tuesday? ↗
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS